Stability of medication in early psychosis: A comparison between second-generation and low-dose first-generation antipsychotics

Early Intervention in Psychiatry

Volumn 3, Issue 1, 2009, Pages 58-65

  Opjordsmoen, Stein ^a,b   Melle, Ingrid ^a,b   Friis, Svein ^a,b   Haahr, Ulrik ^c   Johannessen, Jan O ^d   Larsen, Tor K ^b,d   Rund, Bjørn R ^b   Simonsen, Erik ^c   Vaglum, Per ^b   McGlashan, Thomas H ^e  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e YALE UNIVERSITY   (United States)

Author keywords

First and second generation antipsychotics; First episode psychosis; Schizophrenia; Side effect

Indexed keywords

CHLORPROMAZINE; CHLORPROTHIXENE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; RISPERIDONE; SERTINDOLE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; AKATHISIA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPHORIA; DYSTONIA; HUMAN; INDIVIDUALIZATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PARKINSONISM; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHI-SQUARE DISTRIBUTION; CLOPENTHIXOL; CLOZAPINE; FEMALE; HUMANS; IMIDAZOLES; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERPHENAZINE; PSYCHOTIC DISORDERS; RISPERIDONE; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 64949201872     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2008.00103.x     Document Type: Article

References (39)

1. Fleischhacker WW. Pharmacological treatment of schizophrenia: A review. In: Maj M, Sartorius N, eds. WPA Series Evidence and Experience in Psychiatry, Vol. 2, Schizophrenia. Chichester: John Wiley, 1999; 75-107.
2. Robinson DG, Woerner MG, Alvir JMJ et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-9.
3. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet 2003; 361: 1581-9.
4. Lieberman JA, Tollefson G, Tohen M et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396-404.
5. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology and psychopharmacology in schizophrenia. Am J Psychiatry 2003; 159: 13-23.
6. Gilmer TP, Dolder CR, Lacro JP et al. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161: 692-9.
7. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103-8.
8. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state medicaid program. Psychiatr Serv 2003; 54: 719-23.
9. Hamann J, Langer B, Leucht S, Busch R, Kissling W. Medical decision making in antipsychotic drug choice for schizophrenia. Am J Psychiatry 2004; 161: 1301-4.
10. Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782-91.
11. Lieberman JA, Tollefson G, Tohen M et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396-404.
12. Schooler N, Rabinowitz J, Davidson M et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 2005; 162: 947-53.
13. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
14. Beasley CM Jr, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics. An integrated analysis. J Clin Psychopharmacol 2007; 27: 252-8.
15. Jones PB, Barnes TRE, Davies L et al. Randomized controlled trial of the effect on quality of life of second- versus first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63: 1079-87.
16. McCue RE, Waheed R, Urcuyo L et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006; 189: 433-40.
17. Melle I, Larsen TK, Haahr U et al. Reducing the duration of untreated first-episode psychosis. Effects on clinical presentation. Arch Gen Psychiatry 2004; 61: 143-50.
18. Rund BR, Melle I, Friis S et al. Neurocognitive dysfunction in first-episode psychosis: Correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry 2004; 161: 466-72.
19. First MB, Spitzer RL, Gibbon M, Williams JBW. Structural Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID I/P, Version 2.0). New York: New York State Psychiatric Institute, Biometrics Research Department, 1995.
20. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
21. Pedersen G, Hagtvedt KA, Karterud S. Generalizability studies of the Global Assessment of Functioning - Split version. Compr Psychiatry 2007; 48: 88-94.
22. Friis S, Larsen TK, Melle I et al. Methodological pitfalls in early detection studies: The NAPE Lecture 2002: Nordic Association for Psychiatric Epidemiology. Acta Psychiatr Scand 2003; 107: 3-9.
23. Gerlach J, Korsgaard S, Clemmesen P et al. The St. Hans rating scale for extrapyramidal syndromes: Reliability and validity. Acta Psychiatr Scand 1993; 87: 244-52.
24. McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR. Use patters for antipsychotic medications in medicaid patients with schizophrenia. J Clin Psychiatry 1999; 60 (Suppl. 19): 5-11.
25. McEvoy JP, Lieberman JA, Perkins DA et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164: 1050-60.
26. Kinon BJ, Liu-Seifert H, Adams DH, Citrome L. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J Clin Psychopharmacol 2006; 26: 632-7.
27. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006; 6: 8.
28. Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum H. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. J Clin Psychopharmacol 2006; 26: 666-7.
29. De Lima MS, Mari JJ, Breier A, Costa AM, De Sena EP, Hotopf M. Quality of life in schizophrenia: A multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J Clin Psychiatry 2005; 66: 831-8.
30. Martin JLR, Pérez V, Sacristán M, Rodríguez-Artalejo F, Martínez C, Álvarez E. Meta-analysis of drop-out rates in randomized clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry 2006; 21: 11-20.
31. Schooler NR. The efficacy and safety of conventional and atypical antipsychotics in first-episode schizophrenia: A review of the literature. Clin Schizophr Relat Psychoses 2007; 1: 27-42.
32. Robinson D, Woerner MG, Alvir JMJ et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-7.
33. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: A comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005; 162: 1888-95.
34. Marder SR. Editorial. Lessons from each drug trial. Am J Psychiatry 2007; 164: 375-6.
35. Naber D. Subjective effects of antipsychotic treatment (Editorial). Acta Psychiatr Scand 2005; 111: 81-3.
36. Naber D, Riedel M, Klimke A et al. Randomized double blind comparison of olanzapine versus clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005; 111: 106-15.
37. Voruganti L, Cortese L, Owyeumi L et al. Switching from conventional to novel antipsychotic drugs: Results of a prospective naturalistic study. Schizophr Res 2002; 57: 201-8.
38. Birkenaes AB, Birkeland KI, Engh JA et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008; 28: 132-7.
39. Birkenaes AB, Birkeland KI, Friis S, Opjordsmoen S, Andreassen OA. Hormonal markers of metabolic dysregulation in patients with severe mental disorders following olanzapine treatment under real life conditions. J Clin Psychopharmacol (in press).